## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claim 1. (original) A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

wherein

 $R^1$  is selected from –H,  $C_{6-10}$ aryl,  $C_{2-6}$ heteroaryl,  $C_{6-10}$ aryl- $C_{1-4}$ alkyl, and  $C_{2-6}$ heteroaryl- $C_{1-4}$ alkyl, wherein said  $C_{6-10}$ aryl,  $C_{2-6}$ heteroaryl,  $C_{6-10}$ aryl- $C_{1-4}$ alkyl, and  $C_{2-6}$ heteroaryl- $C_{1-4}$ alkyl are optionally substituted with one or more groups selected from -R, –NO<sub>2</sub>, -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1-6}$ alkyl;

 $R^2$  is selected from -H,  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl, wherein said  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1-6}$ alkyl; and

 $R^3$  is selected from  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl, wherein said  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1-6}$ alkyl.

Claim 2. (original) A compound according to claim 1, wherein

 $R^1$  is  $-CH_2-R^4$ , wherein  $R^4$  is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, wherein said phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl are optionally substituted with one or more groups selected from  $C_{1-6}$ alkyl, halogenated  $C_{1-6}$ alkyl, -NO<sub>2</sub>, -CF<sub>3</sub>,  $C_{1-6}$  alkoxy, chloro, fluoro, bromo, and iodo;

R<sup>2</sup> is selected from –H and C<sub>1-3</sub>alkyl; and R<sup>3</sup> is selected from C<sub>1-6</sub>alkyl, and C<sub>3-6</sub>cycloalkyl.

Claim 3. (original) A compound according to claim 2, wherein R<sup>4</sup> is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; pyrrolyl and thiazolyl;

R<sup>2</sup> is selected from –H and methyl; and

R<sup>3</sup> is selected from methyl, ethyl, propyl and isopropyl.

Claim 4. (original) A compound according to claim 1, wherein

 $R^1$  is -H;

R<sup>2</sup> is selected from –H and C<sub>1-3</sub>alkyl; and

R<sup>3</sup> is selected from C<sub>1-6</sub>alkyl, and C<sub>3-6</sub>cycloalkyl.

Claim 5. (original) A compound according to claim 1, wherein the compound is selected from:

Methyl 3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzyl-piperazin-1-yl)methyl]phenylcarbamate;

Methyl-3-{{4-[(diethylamino)carbonyl]phenyl}[4-(thien-2-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(thien-3-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(2-furylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(3-furylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(1H-imidazol-2-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(pyridin-2-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(pyridin-4-yl-methyl) piperazin-1-yl} methyl}phenylcarbamate;

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-2-ylmethyl)-piperazin-1-yl]methyl}phenylcarbamate;

[3-[[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-carbamic acid methyl ester;

[3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]- carbamic acid, methyl ester;

[3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]- carbamic acid, methyl ester;

Methyl 3-{(R)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{(S)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{(R)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-5-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{(S)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-5-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

[3-[[4-[(diethylamino)carbonyl]phenyl]-1-piperazinylmethyl]phenyl]- carbamic acid, methyl ester;

enantiomers thereof; and pharmaceutically acceptable salts thereof.

Claims 6-7 (cancelled).

Claim 8. (previously presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

Claim 9. (previously presented) A method for the therapy of pain in a warm-blooded animal, comprising: administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.

Claims 10-12. (canceled)

Claim 13. (original) A process for preparing a compound of formula VII:

comprising:

reacting a compound of formula VIII

<u>VIII</u>

with a C<sub>1-6</sub>alkylcarbamate to form the compound of formula VII,

## wherein

 $\mathsf{R}^8$  is selected from C<sub>1-6</sub>alkyl-O-C(=O)-, C<sub>6-10</sub>aryl-C<sub>1-4</sub>alkyl, and C<sub>2-6</sub>heteroaryl-C<sub>1-4</sub>alkyl, wherein said C<sub>1-6</sub>alkyl-O-C(=O)-, C<sub>6-10</sub>aryl-C<sub>1-4</sub>alkyl, and C<sub>2-6</sub>heteroaryl-C<sub>1-4</sub>alkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C<sub>1-6</sub>alkyl;

X is selected from halogen, triflate, and sulfonamide; and  $R^{11}$  is a  $C_{1\text{-}6} alkyl.$ 

Claim 14. (original) A process for preparing a compound of formula X,

## comprising:

reacting a compound of formula IX,

with  $R^4$ -CHO to form the compound of formula X, wherein

 $R^4$  is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, wherein said phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl are optionally substituted with one or more groups selected from  $C_{1-6}$ alkyl, halogenated  $C_{1-6}$ alkyl, -NO<sub>2</sub>, -CF<sub>3</sub>,  $C_{1-6}$  alkoxy, chloro, fluoro, bromo, and iodo;

 $R^2$  is selected from -H,  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl, wherein said  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -l, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1-6}$ alkyl; and

 $R^3$  is selected from -H,  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl, wherein said  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1-6}$ alkyl.

Claim 15. (original) A compound of formula XI, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

wherein

 $R^1$  is selected from –H,  $C_{6-10}$ aryl,  $C_{2-6}$ heteroaryl,  $C_{6-10}$ aryl- $C_{1-4}$ alkyl, and  $C_{2-6}$ heteroaryl- $C_{1-4}$ alkyl, wherein said  $C_{6-10}$ aryl,  $C_{2-6}$ heteroaryl,  $C_{6-10}$ aryl- $C_{1-4}$ alkyl, and  $C_{2-6}$ heteroaryl- $C_{1-4}$ alkyl are optionally substituted with one or more groups selected from -R, –NO<sub>2</sub>, -OR, -Cl, -Br, -I, -F, -CF<sub>3</sub>, -C(=O)R, -C(=O)OH, -NH<sub>2</sub>, -SH, -NHR, -NR<sub>2</sub>, -SR, -SO<sub>3</sub>H, -SO<sub>2</sub>R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR<sub>2</sub>, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or  $C_{1-6}$ alkyl.